MSB 4.52% 95.0¢ mesoblast limited

Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-376

  1. 308 Posts.
    lightbulb Created with Sketch. 76
    Alot of negativity here so let me summize
    chf : works reduces mortality - didn't meet primary plenty of data
    Gvhd: kicked back for another RCT
    clbp : heaps of data primary endpoint was reached for those <5 years reported CLBP

    the result? Even if we don't get approval, the treatment works and have a plethora of data to prove efficacy across all indications, also the current data will help model further trials around FDA approval (with better understanding of the current trials, endpoints reached, etc)

    even though I believe we will get approval for at least ONE indication this year, that is all we really need.
    shorters love this stock for a reason.

    Bottom line: it works.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
-0.045(4.52%)
Mkt cap ! $1.084B
Open High Low Value Volume
$1.00 $1.01 94.5¢ $2.669M 2.769M

Buyers (Bids)

No. Vol. Price($)
1 2053 95.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.5¢ 13191 2
View Market Depth
Last trade - 16.10pm 20/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.